Mentari Therapeutics(MTRI)
$15.56+2.35 (+17.79%)
MTRI
Mentari Therapeutics financials statements
$15.56
At close:+2.35 (+17.79%)
Want to see MTRI full AI Analyst Report?
Mentari Therapeutics (MTRI) Ratios
397 Followers
Mentari Therapeutics Ratios
MTRI's free cash flow for Q1 2027 was C$-1.14M. For the 2027 fiscal year, MTRI's free cash flow was increased by C$0.00 and operating cash flow was C$-1.14M. See a summary of the company’s cash flow.
| Ratios | Jun 26 | Jun 25 | Jun 24 | Jun 23 | Jun 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.37 | 6.99 | 4.41 | 5.66 | 2.89 |
| Quick Ratio | 1.37 | 6.47 | 3.78 | 4.86 | 2.14 |
| Cash Ratio | 1.12 | 6.02 | 3.33 | 4.45 | 1.86 |
| Solvency Ratio | -6.06 | -3.55 | -2.70 | -3.65 | -3.79 |
| Operating Cash Flow Ratio | -4.42 | -4.22 | -3.54 | -3.64 | -3.65 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | C$ 721.65K | C$ 10.72M | C$ 6.07M | C$ 9.32M | C$ 7.58M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.05 | 0.08 | 0.03 | 0.06 |
| Debt-to-Equity Ratio | 0.00 | 0.06 | 0.10 | 0.03 | 0.09 |
| Debt-to-Capital Ratio | 0.00 | 0.05 | 0.09 | 0.03 | 0.08 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 2.82 | 1.16 | 1.28 | 1.17 | 1.41 |
| Debt Service Coverage Ratio | -858.58 | -19.45 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | -924.78 | -21.22 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.03 | 11.42 | 2.53 | 3.20 | 911.51 |
| Net Debt to EBITDA | 0.24 | 1.42 | 0.79 | 1.09 | 0.52 |
| Profitability Margins | |||||
| Gross Profit Margin | 22.35% | 34.53% | 23.94% | 33.93% | 49.89% |
| EBIT Margin | -0.31% | -157.62% | -166.79% | -202.60% | -1265.95% |
| EBITDA Margin | -0.29% | -146.80% | -153.64% | -188.19% | -1218.98% |
| Operating Profit Margin | -0.31% | -160.20% | -176.92% | -202.60% | -1265.95% |
| Pretax Profit Margin | -0.36% | -165.14% | -166.79% | -191.86% | -1707.32% |
| Net Profit Margin | -0.40% | -165.14% | -166.94% | -192.18% | -1707.32% |
| Continuous Operations Profit Margin | -0.36% | -165.14% | -166.94% | -192.18% | -1707.32% |
| Net Income Per EBT | 110.44% | 100.00% | 100.09% | 100.17% | 100.00% |
| EBT Per EBIT | 114.94% | 103.08% | 94.27% | 94.70% | 134.86% |
| Return on Assets (ROA) | -414.54% | -52.39% | -64.92% | -56.34% | -112.99% |
| Return on Equity (ROE) | -1168.44% | -60.76% | -83.37% | -65.74% | -159.16% |
| Return on Capital Employed (ROCE) | -920.47% | -57.63% | -82.57% | -69.21% | -113.16% |
| Return on Invested Capital (ROIC) | -920.47% | -55.85% | -79.99% | -67.13% | -108.52% |
| Return on Tangible Assets | -414.54% | -58.47% | -76.45% | -65.36% | -135.31% |
| Earnings Yield | -194.63% | -257.32% | -400.46% | -350.16% | -7060.61% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 10.63 | 13.03 | 15.88 | 9.61 |
| Payables Turnover | 2660.41 | 8.75 | 5.58 | 5.02 | 0.36 |
| Inventory Turnover | 0.00 | 3.37 | 2.81 | 1.69 | 0.17 |
| Fixed Asset Turnover | 14.37 | 4.98 | 3.68 | 5.72 | 0.94 |
| Asset Turnover | 1048.33 | 0.32 | 0.39 | 0.29 | 0.07 |
| Working Capital Turnover Ratio | 540.74 | 0.56 | 0.57 | 0.47 | 0.15 |
| Cash Conversion Cycle | -0.14 | 101.00 | 92.53 | 166.20 | 1178.23 |
| Days of Sales Outstanding | 0.00 | 34.34 | 28.01 | 22.98 | 37.96 |
| Days of Inventory Outstanding | 0.00 | 108.39 | 129.88 | 215.91 | 2143.93 |
| Days of Payables Outstanding | 0.14 | 41.73 | 65.36 | 72.69 | 1003.66 |
| Operating Cycle | 0.00 | 142.73 | 157.89 | 238.89 | 2181.89 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -20.76 | -79.58 | -18.33 | -59.49 | -13901.66 |
| Free Cash Flow Per Share | -20.76 | -79.58 | -18.36 | -60.81 | -13936.54 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | 0.00 | -751.73 | -45.01 | -398.48 |
| Capital Expenditure Coverage Ratio | 0.00 | 0.00 | -751.73 | -45.01 | -398.48 |
| Operating Cash Flow Coverage Ratio | 0.00 | -10.48 | -7.26 | -18.59 | -15.25 |
| Operating Cash Flow to Sales Ratio | -0.00 | -1.57 | -1.52 | -1.76 | -14.30 |
| Free Cash Flow Yield | -133.93% | -244.86% | -364.96% | -328.02% | -5930.44% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -0.50 | -0.39 | -0.25 | -0.29 | -0.01 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.64 | 0.42 | 0.55 | 0.24 |
| Price-to-Book (P/B) Ratio | 6.00 | 0.24 | 0.21 | 0.19 | 0.02 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -0.75 | -0.41 | -0.27 | -0.30 | -0.02 |
| Price-to-Operating Cash Flow Ratio | -0.75 | -0.41 | -0.27 | -0.31 | -0.02 |
| Price-to-Earnings Growth (PEG) Ratio | 0.01 | 0.01 | 0.00 | 0.00 | -0.00 |
| Enterprise Value Multiple | -0.46 | 0.99 | 0.52 | 0.80 | 0.50 |
| Enterprise Value | 4.26M | -7.16M | -3.69M | -6.25M | -6.67M |
| EV to EBITDA | -0.46 | 0.99 | 0.52 | 0.80 | 0.50 |
| EV to Sales | 0.00 | -1.45 | -0.80 | -1.51 | -6.12 |
| EV to Free Cash Flow | -0.49 | 0.92 | 0.53 | 0.84 | 0.43 |
| EV to Operating Cash Flow | -0.49 | 0.92 | 0.53 | 0.86 | 0.43 |
| Tangible Book Value Per Share | 2.58 | 121.04 | 19.48 | 82.86 | 8003.44 |
| Shareholders’ Equity Per Share | 2.58 | 137.64 | 24.16 | 98.75 | 10425.18 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | -0.00 | -0.00 | 0.00 |
| Revenue Per Share | 7629.21 | 50.64 | 12.07 | 33.78 | 971.84 |
| Net Income Per Share | -30.17 | -83.63 | -20.14 | -64.92 | -16592.43 |
| Tax Burden | 1.10 | 1.00 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.15 | 1.05 | 1.00 | 0.95 | 1.35 |
| Research & Development to Revenue | 0.00 | 0.58 | 0.70 | 0.90 | 6.68 |
| SG&A to Revenue | 0.59 | 1.33 | 1.26 | 1.41 | 6.30 |
| Stock-Based Compensation to Revenue | 0.00 | 0.02 | 0.03 | 0.07 | 0.64 |
| Income Quality | 0.69 | 0.95 | 0.91 | 0.92 | 0.84 |
Currency in CAD
